Seroatlas · Human Serome Atlas

MARK3

MAP/microtubule affinity-regulating kinase 3

Also known as: CTAK1, KP78, MARK3_HUMAN, PAR-1A

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P27448
Gene
MARK3
Ensembl
ENSG00000075413
Chromosome
14
Canonical length
753 aa
Protein class
Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins

OverviewNCBI Gene

The protein encoded by this gene is activated by phosphorylation and in turn is involved in the phosphorylation of tau proteins MAP2 and MAP4. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011]

Canonical amino-acid sequenceUniProt

753 residues, UniProt reviewed canonical sequence.

>P27448|MARK3
     1  MSTRTPLPTV NERDTENHTS HGDGRQEVTS RTSRSGARCR NSIASCADEQ PHIGNYRLLK
    61  TIGKGNFAKV KLARHILTGR EVAIKIIDKT QLNPTSLQKL FREVRIMKIL NHPNIVKLFE
   121  VIETEKTLYL IMEYASGGEV FDYLVAHGRM KEKEARSKFR QIVSAVQYCH QKRIVHRDLK
   181  AENLLLDADM NIKIADFGFS NEFTVGGKLD TFCGSPPYAA PELFQGKKYD GPEVDVWSLG
   241  VILYTLVSGS LPFDGQNLKE LRERVLRGKY RIPFYMSTDC ENLLKRFLVL NPIKRGTLEQ
   301  IMKDRWINAG HEEDELKPFV EPELDISDQK RIDIMVGMGY SQEEIQESLS KMKYDEITAT
   361  YLLLGRKSSE LDASDSSSSS NLSLAKVRPS SDLNNSTGQS PHHKVQRSVS SSQKQRRYSD
   421  HAGPAIPSVV AYPKRSQTST ADSDLKEDGI SSRKSSGSAV GGKGIAPASP MLGNASNPNK
   481  ADIPERKKSS TVPSSNTASG GMTRRNTYVC SERTTADRHS VIQNGKENST IPDQRTPVAS
   541  THSISSAATP DRIRFPRGTA SRSTFHGQPR ERRTATYNGP PASPSLSHEA TPLSQTRSRG
   601  STNLFSKLTS KLTRRNMSFR FIKRLPTEYE RNGRYEGSSR NVSAEQKDEN KEAKPRSLRF
   661  TWSMKTTSSM DPGDMMREIR KVLDANNCDY EQRERFLLFC VHGDGHAENL VQWEMEVCKL
   721  PRLSLNGVRF KRISGTSIAF KNIASKIANE LKL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MARK3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.46
Highest tissue expression
59 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 59 nTPM
  • bone marrow: 51 nTPM
  • heart muscle: 51 nTPM
  • tongue: 40 nTPM
  • adrenal gland: 36 nTPM
  • pancreas: 32 nTPM

Single-cell type

  • epicardial cells: 682 nCPM
  • neutrophils: 666 nCPM
  • cardiomyocytes: 631 nCPM
  • neutrophil progenitors: 478 nCPM
  • esophageal apical cells: 453 nCPM
  • adrenal cortex cells: 416 nCPM

Immune cell

  • eosinophil: 102 nTPM
  • T-reg: 3.2 nTPM
  • memory CD8 T-cell: 2.9 nTPM
  • neutrophil: 2.6 nTPM
  • naive CD4 T-cell: 2.4 nTPM
  • memory CD4 T-cell: 2.3 nTPM

Brain region

  • pons: 14 nTPM
  • cerebellum: 13 nTPM
  • basal ganglia: 13 nTPM
  • white matter: 12 nTPM
  • cerebral cortex: 12 nTPM
  • choroid plexus: 12 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about MARK3.

Disease | AllUniProt

Conditions MARK3 is implicated in, by any mechanism.

  • Visual impairment and progressive phthisis bulbi (VIPB) MIM:618283

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 117 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Visual impairment and progressive phthisis bulbi

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.63
gnomAD pLI
0
gnomAD missense Z
1.51
DepMap mean gene effect
0.03
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MARK3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MARK3 as an antibody target. Whether an autoantibody or antibody against MARK3 could matter depends on whether native MARK3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MARK3 is annotated at the cell surface, where native MARK3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label MARK3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/MARK3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...